FREQUENTLY ASKED QUESTIONS
This FAQ is for general information about Cellular Biomedicine (“CBMG” or the “Company”).
This information was last updated on June 1, 2017 and should be considered current as of that date.
When was CBMG established?Where is CBMG located?What are CBMG’s products?Where are CBMG’s target markets?What are CBMG’s ticker symbol, exchange, and CUSIP?How many shares of CBMG are outstanding?What is CBMG’s fiscal year and corresponding quarter-end datesHow can I invest in CBMG?Who is CBMG’s IR contact?Who is CBMG’s transfer agent?
CBMG was established in 2009.
CBMG has offices in Cupertino, California. We also have offices across the world, including in Hong Kong, R&D facilities in Wuxi, China, and Beijing, China and an international-standard protocol-compliant manufacturing facility in Shanghai, China.
We are developing our business on two cellular therapeutic platforms: Immuno-Oncology and Stem Cell Regenerative Medicine.
CBMG’s primary target market is Greater China. We are also expanding into the global market by seeking international strategic collaborations in the U.S. and abroad.
The ticker symbol is NASDAQ: CBMG, and the CUSIP number is 15117P102.
As of April 31, 2017, there were 14,290,668 shares of common stock, par value $.001 per share issued and outstanding.
CBMG operates on a fiscal year that runs from January 1 to December 31. Quarter-ends are: March 31 (Q1), June 30 (Q2), and September 30 (Q3
You can purchase CBMG common stock through a registered brokerage or stock purchase service provider of your choice. You are unable to buy stock directly from CBMG.
Sarah Kelly, Director of Corporate Communications, CBMG Phone: +1 408-973-7884 (USA) or +86 21 5406 9990 (China) Email: firstname.lastname@example.org
The Company’s transfer agent and registrar for the common stock is Corporate Stock Transfer, Inc. located in Denver, Colorado. http://www.corporatestock.com/